All In Biotech

Drug Trial Radar · NCT00906399

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,516 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,516

Actual

Start

Jun 2009

Primary completion

Oct 2012

Study completion Oct 2013

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
May 21, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year. The secondary objectives of this study are to determine whether peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the progression of disability.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • BIIB017 (peginterferon beta-1a)Drug

    Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.

  • PlaceboDrug

    Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR) at 1 YearTime frame: 1 Year

Locations

178 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Ponte Vedra Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Des Moines, Iowa

  • Research Site

    Lexington, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Teaneck, New Jersey

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Akron, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Franklin, Tennessee

  • Research Site

    Round Rock, Texas

  • Research Site

    Brussels, Belgium

  • Research Site

    Sint-Truiden, Belgium

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    London, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Santiago, Chile

  • Research Site

    Bogotá, Colombia

  • Research Site

    Barranquilla, Atlántico, Colombia

  • Research Site

    Bogota, Cundinamarca, Colombia

  • Research Site

    Osijek, Croatia

  • Research Site

    Zagreb, Croatia

  • Research Site

    Brno, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Ostrava, Czechia

  • Research Site

    Ostrava - Vitkovice, Czechia

  • Research Site

    Ostrava-Poruba, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Pärnu, Estonia

  • Research Site

    Tallinn, Estonia

  • Research Site

    Tartu, Estonia

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.